Papers on sulfonylurea

213 papers11 new in 30 days

Tuesday, October 27

Current Opinion in Clinical Nutrition and Metabolic CareOct 27

The use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits

ReviewGLP-1 receptor agonists

Paper

Monday, October 26

ESC Congress 2026 AbstractOct 26

Several diabetes drugs are linked to lower aortic aneurysm risk

In 3,432,327 adults with type 2 diabetes followed for a mean of 9.2 years, six medication categories were associated with a lower risk of aortic aneurysm.In 3,432,327 adults with type 2 diabetes followed for a mean of 9.2 years, six medication categories were associated with a lower risk of aortic aneurysm.

A cutaway aorta with a bulging wall stands between smaller smooth and swollen aortas, beside upright groups of people and separate organs.

Cohort · 3,432,327 peopleAortic aneurysm

Paper

ESC Congress 2026 AbstractOct 26

Characterization of cardiovascular risk profile and therapeutic management in patients with type 2 diabetes mellitus: insight from the CardioMET Italian registry

Cohort study of 1,927 peopleType 2 diabetes

Paper

ESC Congress 2026 AbstractOct 26

GLP-1 drugs not linked to excess risk in recovered heart failure

Crude rates of hospitalization or death were 18.6 per 100 person-years with GLP-1 drugs against 16.7 with other diabetes drugs, with an adjusted hazard ratio of 1.05.Crude rates of hospitalization or death were 18.6 per 100 person-years with GLP-1 drugs against 16.7 with other diabetes drugs, with an adjusted hazard ratio of 1.05.

Cohort · 2,061 peopleInterventions

Paper

Sunday, October 18

EndocrineOct 18

Periconceptional and early-pregnancy exposure to SGLT2 inhibitors and congenital malformations: a systematic review and meta-analysis

Meta-analysis of observational studiesPregnancy

Paper

Friday, October 16

DiabetologiaOct 16

Israeli adults newly diagnosed with type 2 diabetes were older

Median age at diagnosis rose from 63.0 years in 2005–2008 to 66.7 years in 2020–2023, alongside more coexisting illnesses and lower blood sugar.Median age at diagnosis rose from 63.0 years in 2005–2008 to 66.7 years in 2020–2023, alongside more coexisting illnesses and lower blood sugar.

Cohort · 181,593 peopleType 2 diabetes

Paper

Molecular Aspects of MedicineOct 16

Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review

ReviewCancer

Paper

Sunday, October 4

Osteoporosis InternationalOct 4

Prevalence, risk factors and adverse health outcomes of osteosarcopenia in middle-aged and older adults with type 2 diabetes mellitus-a scoping review

Systematic review of observational studiesOsteosarcopenia

Paper

Thursday, October 1

LancetOct 1

Orforglipron matches insulin glargine on cardiovascular safety

Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.

Randomized trial in 2,749 peopleOrforglipron

Paper

Wednesday, September 30

LancetSep 30

Retatrutide reduces bodyweight in obesity and type 2 diabetes

Bodyweight fell by up to 18.8% with weekly retatrutide compared with 5.1% on placebo at week 80 in adults with obesity and type 2 diabetes.Bodyweight fell by up to 18.8% with weekly retatrutide compared with 5.1% on placebo at week 80 in adults with obesity and type 2 diabetes.